Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Digene DNA Pap Test Cost-Benefit Studies Set Stage For Reimbursement

This article was originally published in The Gray Sheet

Executive Summary

Recent studies evaluating the cost-effectiveness of Digene's DNA Pap test for cervical cancer may help support reimbursement for a primary screening indication pending FDA approval, the firm says
Advertisement

Related Content

Digene Still Expecting HPV DNA Pap Test Primary Screen Approval By 2003
Cytyc Gets Digene After Long Courtship, On Verge Of New Indication
NCI HPV Trial Data Re-Evaluated By Digene To Support PMA Supplement
NCI HPV Trial Data Re-Evaluated By Digene To Support PMA Supplement
Advertisement
UsernamePublicRestriction

Register

MT016534

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel